Berzosertib (VE-822) is a highly potent and selective first-in-class ATR inhibitor. It affects ATR-Chk1 and DNA damage response signaling by suppressing Chk1 phosphorylation and disrupting cell cycle checkpoints, effectively inhibiting cancer cell proliferation and promoting apoptosis.
Berzosertib (VE-822) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Berzosertib (VE-822) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.